{"id":"W4205675137","doi":"10.1007/s13555-021-00649-y","title":"Deucravacitinib in Moderate to Severe Psoriasis: Clinical and Quality-of-Life Outcomes in a Phase 2 Trial","year":2022,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":48,"is_retracted":false,"has_abstract":true,"ca_institutions":"Queen's University; Probity Medical Research","funders":"LEO Pharma; Kyowa Hakko Kirin; Sanofi Genzyme; Incyte; Dermira; Sun Pharma; Regeneron Pharmaceuticals; Genentech; Valeant Pharmaceuticals International; Sanofi; Celgene; Biogen; GlaxoSmithKline; Amgen; Meiji Seika Pharma; Pfizer; Galderma; Ortho Dermatologics; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Psoriasis; Quality of life (healthcare); Clinical trial; Medicine; Phase (matter); Quality (philosophy); Intensive care medicine; Internal medicine; Dermatology; Nursing; Philosophy; Physics","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006438378,0.0001728074,0.0008285859,0.0002181535,0.0001295863,0.000005170922,0.0001161463,0.0002102668,0.0001479283],"category_scores_gemma":[0.00008919351,0.0001525221,0.00007931253,0.0001483793,0.0001409178,0.00004618505,0.00007767589,0.0002515496,0.000007898563],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000008004579,"about_ca_system_score_gemma":0.00006674932,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001133021,"about_ca_topic_score_gemma":0.0001334034,"domain_scores_codex":[0.9970568,0.001586928,0.0007313209,0.0003335673,0.00003194119,0.0002594066],"domain_scores_gemma":[0.9990439,0.000598309,0.0001324191,0.0001737074,0.00001412064,0.00003752294],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.1745008,0.002142766,0.7628941,0.00001653409,0.0004982258,0.00005784467,0.002525371,0.000006466444,0.001261343,0.002460388,0.0001734109,0.05346275],"study_design_scores_gemma":[0.6552362,0.002500074,0.3201757,0.00001979331,0.00006612806,0.0002883469,0.001907225,0.00002091688,0.002848154,0.003307431,0.01289237,0.0007376525],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9926581,0.005134583,0.000009366086,0.0009018469,0.0005822881,0.0005317683,0.00008454337,0.00001850557,0.00007897957],"genre_scores_gemma":[0.9976459,0.0009086845,0.00004215031,0.001029223,0.00001239848,0.0002055869,0.00004504793,0.00001007441,0.0001009015],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4807354,"threshold_uncertainty_score":0.621967,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08333823224810268,"score_gpt":0.367916018610268,"score_spread":0.2845777863621653,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}